Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 9Thoracic 8Gynecologic 7Genitourinary 6Other hematologic neoplasm 5Sarcoma 3Myeloid 3Lymphoid 3Gastrointestinal 3CNS 3Breast 3Other 2Classical hematology 2Dermatologic 1

Conditions

Myelodysplastic Syndromes 2Anemia, Refractory, with Excess of Blasts 2Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia 1Anemia, Refractory 1

Interventions

Cyclophosphamide 58Busulfan 47fludarabine phosphate 45Cyclosporine 34Mycophenolic Acid 31Whole-Body Irradiation 29Peripheral Blood Stem Cell Transplantation 29fludarabine 27Antilymphocyte Serum 27Tacrolimus 26Methotrexate 25Melphalan 25Filgrastim 20Radiotherapy 19Darbepoetin alfa 19Cytarabine 19Cord Blood Stem Cell Transplantation 18Epoetin Alfa 17Granulocyte Colony-Stimulating Factor 14Methylprednisolone 13thymoglobulin 10Thiotepa 9Etoposide 9Alemtuzumab 9eltrombopag 8Stem Cell Transplantation 8olaparib 7sargramostim 6hetrombopag 6Rituximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Amifostine × Classical hematology × Clear all
NCT00098683 2014-02-13

Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes

Children's Oncology Group

Phase 2 Completed
10 enrolled
Classical hematologyMyeloid

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases

NCT00003827 2013-12-04

Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 2 Unknown
25 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡